We showed that blocking VEGFR2 signaling with sunitinib inhibits the ITGB3+ EV–mediated increase in endothelial permeability, suggesting that sunitinib or other VEGF pathway inhibitors might be useful for the prevention or treatment of BC brain metastasis. Here, KDR is linked to breast cancer.